HOMB Bucks Yearly Trend, Surges Upwards Today.

This afternoon we watched Home BancShares rise 1.0% to a price of $20.95 per share. The mid-cap Banking company is now trading -17.82% below its average target price of $25.5. Analysts have set target prices ranging from $25.0 to $27.0 per share for Home BancShares, and have given the stock an average rating of buy.

Home BancShares has an average level of shares sold short, at 5.4% of its total share float. The stock's short ratio (also called days to cover) is 4.93. Since 7.16% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Institutional investors own 63.8% of Home BancShares's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Home BancShares

Date Reported Holder Percentage Shares Value
2022-12-31 Blackrock Inc. 11% 22,802,579 $477,828,041
2022-12-31 Vanguard Group, Inc. (The) 10% 21,267,212 $445,654,425
2022-12-31 T. Rowe Price Investment Management, Inc. 5% 9,656,167 $202,344,978
2022-12-31 State Street Corporation 4% 8,246,950 $172,814,836
2022-12-31 American Century Companies, Inc. 2% 4,708,020 $98,656,558
2022-12-31 Dimensional Fund Advisors LP 2% 4,062,105 $85,121,409
2022-12-31 Geode Capital Management, LLC 2% 3,475,714 $72,833,586
2023-03-31 Copeland Capital Management, LLC 2% 3,100,087 $64,962,322
2022-12-31 Northern Trust Corporation 1% 2,950,248 $61,822,446
2022-12-31 Wellington Management Group, LLP 1% 2,840,035 $59,512,933
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.